Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Multiple Myeloma 20Lymphoma, Non-Hodgkin 20Leukemia, Myeloid, Acute 11Hodgkin Disease 8Precursor Cell Lymphoblastic Leukemia-Lymphoma 7Myelodysplastic Syndromes 6Leukemia, Lymphocytic, Chronic, B-Cell 6Leukemia, Myelogenous, Chronic, BCR-ABL Positive 5Lymphoma, Mantle-Cell 3Lymphoma, Follicular 3Gliosarcoma 3Glioblastoma 3Sezary Syndrome 2Mycosis Fungoides 2Lymphoma, T-Cell, Cutaneous 2Lymphoma, Large-Cell, Immunoblastic 2Lymphoma, Large B-Cell, Diffuse 2Lymphoma, B-Cell, Marginal Zone 2Lymphoma 2Leukemia, Hairy Cell 2Leukemia 2Hematologic Neoplasms 2Glioma 2Burkitt Lymphoma 2Warts 1Waldenstrom Macroglobulinemia 1Sarcoma, Myeloid 1Recurrence 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Pinealoma 1

Interventions

Dexamethasone 43Cyclophosphamide 38fludarabine phosphate 27Cytarabine 26Rituximab 24Methotrexate 21Lenalidomide 21Bortezomib 21Calcium Dobesilate 20fludarabine 19Peripheral Blood Stem Cell Transplantation 19Whole-Body Irradiation 16Mycophenolic Acid 16pembrolizumab 15Gemcitabine 15Etoposide 15pomalidomide 14Melphalan 14Vincristine 13Filgrastim 13Busulfan 13Tacrolimus 12Cyclosporine 12Carboplatin 12Paclitaxel 11carfilzomib 10durvalumab 9Doxorubicin 9Cetuximab 9Brentuximab Vedotin 9

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Recurrence × plerixafor × Clear all
NCT00903968 2020-06-02

Combination Plerixafor (AMD3100)and Bortezomib in Relapsed or Relapsed/Refractory Multiple Myeloma

Dana-Farber Cancer Institute

Phase 1/2 Completed
58 enrolled 13 charts
Plasma cell

Multiple Myeloma, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡